Immune cell therapy plus gemcitabine after pancreas surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 3 trial tests whether adding an immune cell therapy (Immuncell-LC) to the standard chemotherapy drug gemcitabine helps people with resectable pancreatic cancer after surgery. It aims to improve safety and outcomes like preventing the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 20 to 80 years old
- Have pancreatic ductal adenocarcinoma confirmed by biopsy or cell test
- Have had surgery to remove the tumor completely or near-completely (R0 or R1), and at least 2 weeks have passed after surgery (up to 12 weeks)
- No spread to distant organs (for example liver or peritoneum); no distant metastases
- Be well enough for treatment: performance status (ECOG) 0 to 2 and life expectancy of at least 12 weeks
- Plan to start gemcitabine alone as the after-surgery (post-op) chemotherapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
This Phase 2 trial tests a combination of immunotherapy (sintilimab) and chemotherapy (nab-paclitaxel and gemcitabine) given before surgery and again after surgery for pancreatic cancer that can be removed (or close to removable). It aims to improve outcomes by shrinking the tumor before the operation and reducing the chance of return after surgery.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy before surgery for pancreatic cancer that can be removed. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
This trial tests combining a targeted drug (nimotuzumab) with two chemotherapy drugs (nab-paclitaxel and gemcitabine) before and after surgery for pancreatic cancer that can be surgically removed but has high-risk features or is borderline resectable. The goal is to see if this approach improves outcomes.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.